scholarly journals Atypical hemolytic uremic syndrome in high-risk neuroblastoma patient: case report

2021 ◽  
Vol 16 (1) ◽  
pp. 31-35
Author(s):  
A. Yu. Smirnova ◽  
Yu. V. Dinikina ◽  
A. A. Tereshina ◽  
E. P. Evsutina ◽  
M. B. Belogurova

Atypical hemolytic uremic syndrome is a rare disorder uncontrolled complement activation, which is classically manifested by anemia, thrombocytopenia and renal failure. Extrarenal manifestations are observed in 20 % of patients, most of which are associated with damage of the central nervous system. Eculizumab is effective treatment option. The article describes a case report of the severe atypical hemolytic uremic syndrome in a 20 m. o. patient who received immunotherapy with anti-GD2 antibodies (dinutuximab beta) for a high-risk neuroblastoma.

Nephron ◽  
2017 ◽  
Vol 138 (4) ◽  
pp. 324-327 ◽  
Author(s):  
Hironori Nakamura ◽  
Mariko Anayama ◽  
Mutsuki Makino ◽  
Yasushi Makino ◽  
Katsuhiko Tamura ◽  
...  

2018 ◽  
Vol 01 (02) ◽  
pp. 21-27
Author(s):  
N.A. Zharkin ◽  
M.E. Statsenko ◽  
M.M. Stazharova ◽  
N.A. Burova ◽  
S.A. Prokhvatilov ◽  
...  

2019 ◽  
Vol 10 (12) ◽  
pp. 343-344
Author(s):  
Mae-Lan Winchester ◽  
Ryan Platzbecker ◽  
Megan McMahon ◽  
Marc Parrish

2016 ◽  
Vol 40 (3) ◽  
pp. 188-190
Author(s):  
I. Agudo ◽  
T. Souto-Moura ◽  
L. Azevedo ◽  
R. Cavaco ◽  
N. Germano ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document